DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: A pilot study

International Journal of Hyperthermia

Volumn 25, Issue 6, 2009, Pages 405-415

  Craciunescu, Oana I ^a   Blackwell, Kimberly L ^a   Jones, Ellen L ^a   MacFall, James R ^a   Yu, Daohai ^c   Vujaskovic, Zeljko ^a   Wong, Terence Z ^a   Liotcheva, Vlayka ^a   Rosen, Eric L ^b   Prosnitz, Leonard R ^a   Samulski, Thaddeus V ^a   Dewhirst, Mark W ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Hyperthermia; Locally advanced breast cancer; Magnetic resonance imaging; MR prognostic factors; Neoadjuvant therapy

Indexed keywords

DOXORUBICIN; GADOLINIUM PENTETATE MEGLUMINE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; BOLUS INJECTION; BREAST CANCER; CANCER MORPHOLOGY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; IMAGE ANALYSIS; MORPHOPHYSIOLOGICAL TUMOR SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETRIC TEST; PROGNOSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CONTRAST MEDIA; DOXORUBICIN; FEMALE; GADOLINIUM DTPA; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PILOT PROJECTS; PROGNOSIS;

EID: 70849105589     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730903022700     Document Type: Article

References (39)

1. Hortobagyi GN, Singletary SE, McNeese MD. Treatment of locally advanced and inflammatory breast cancer. In: Harris J, editor. Breast Diseases. 1996. pp 585-599.
2. Hortobagyi GN, Buzdar AU. Management of locally advanced breast cancer. Am J Clin Oncol 1988 Oct.;11: 597-601.
3. Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005;91:1-10.
4. Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA, Harms SE. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996;78:91-100.
5. Robinson SP, Howe FA, Rodrigues LM, Stubbs M, Griffiths JR. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin Radiat Oncol 1998;8:197-207.
6. Hylton NM. Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. Magn Reson Imaging Clin N Am 2001;9:321-332, vi.
7. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-266.
8. Knopp MV, von Tengg-Kobligk H, Choyke PL. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther 2003;2:419-426.
9. Helbich TH. Contrast-enhanced magnetic resonance imaging of the breast. Eur J Radiol 2000;34:208-219.
10. Schnall MD. An overview of interpretation strategies for breast MR imaging. Magn Reson Imaging Clin N Am 2001;9:289-294, v-vi.
11. Schnall M, Orel S. Breast MR imaging in the diagnostic setting. Magn Reson Imaging Clin N Am 2006;14: 329-337, vi.
12. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH. Dynamic breast MR imaging: Are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211:101-110.
13. Kuhl CK, Schild HH. Dynamic image interpretation of MRI of the breast. J Magn Reson Imaging 2000;12:965-974.
14. Daniel BL, Yen YF, Glover GH, Ikeda DM, Birdwell RL, Sawyer-Glover AM, Black JW, Plevritis SK, Jeffrey SS, Herfkens RJ. Breast disease: Dynamic spiral MR imaging. Radiology 1998;209:499-509.
15. Flickinger FW, Allison JD, Sherry RM, Wright JC. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 1993;11:617-620.
16. Liney GP, Gibbs P, Hayes C, Leach MO, Turnbull LW. Dynamic contrast-enhanced MRI in the differentiation of breast tumors: User-defined versus semi-automated regionof- interest analysis. J Magn Reson Imaging 1999;10:945-949.
17. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357-367.
18. Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, Gatti M, Biglia N, Sarotto I, Sismondi P, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83:67-76.
19. Julius T, Kemp SE, Kneeshaw PJ, Chaturvedi A, Drew PJ, Turnbull LW. MRI and conservative treatment of locally advanced breast cancer. Eur J Surg Oncol 2005;31: 1129-1134.
20. Wasser K, Klein SK, Fink C, Junkermann H, Sinn HP, Zuna I, Knopp MV, Delorme S. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 2003;13:80-87.
21. Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: Noninvasive monitoring with functional MR imaging pilot study. Radiology 2003; 228:63-69.
22. Drew PJ, Kerin MJ, Mahapatra T, Malone C, Monson JR, Turnbull LW, Fox JN. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol 2001;27:617-620.
23. Szabo BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Bone B. Invasive breast cancer: Correlation of dynamic MR features with prognostic factors. Eur Radiol 2003;13: 2425-2435.
24. Chang YC, Huang CS, Liu YJ, Chen JH, Lu YS, Tseng WY. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Phys Med Biol 2004;49:3593-3602.
25. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-777.
26. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: Initial clinical results. Radiology 2006;239:361-374.
27. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW. Neoadjuvant chemotherapy in breast cancer: Early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006;94:427-435.
28. Wu L, McGough RJ, Arabe OA, Samulski TV. An RF phased array applicator designed for hyperthermia breast cancer treatments. Phys Med Biol 2006;51:1-20.
29. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 1984;10: 787-800.
30. Kurland RJ, Shoop JD, Funkhouser GR. A kinetic model for time development of Gd-DTPA in relaxation enhancement (Abstr.). Magn Reson Imag 1989;7:S177.
31. Belfi CA, Paul CR, Shan S, Ngo FQ. Comparison of the effects of hydralazine on tumor and normal tissue blood perfusion by MRI. Int J Radiat Oncol Biol Phys 1994;29:473-479.
32. Craciunescu OI, Das SK, McCauley RL, MacFall JR, Samulski TV. 3D numerical reconstruction of the hyperthermia induced temperature distribution in human sarcomas using DE-MRI measured tissue perfusion: Validation against non-invasive MR temperature measurements. Int J Hyperthermia 2001;17:221-239.
33. Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005;23:3079-3085.
34. Thrall DE, LaRue SM, Yu D, Samulski T, Sanders L, Case B, Rosner G, Azuma C, Poulson J, Pruitt AF, et al. Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res 2005;11: 5206-5214.
35. Taylor JS, Reddick WE. Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. Adv Drug Deliv Rev 2000;41:91-110.
36. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-259.
37. Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: Trade-off between spatial and temporal resolution. Radiology 2005; 236:789-800.
38. Henderson E, Rutt BK, Lee TY. Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging 1998;16:1057-1073.
39. Ikeda DM, Hylton NM, Kinkel K, Hochman MG, Kuhl CK, Kaiser WA, Weinreb JC, Smazal SF, Degani H, Viehweg P, et al. Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. J Magn Reson Imaging 2001;13:889-895.